- About Breast Cancer
- Community Impact
- Race for the Cure/More Than Pink Walk™
- Team Komen New England
- Impact Ride
- New Haven Breast Cancer Symposium
- Ride for the Cure
- PINK TIE GUYS Boston
- PINK TIE GUYS Greater Hartford
- More Than Pink Luncheon
- Snowshoe for the Cure 2018
- 2019 Catwalk for the Cure
- Get Involved
- Other Ways to Give
New Haven Breast Cancer Symposium
Komen New England Breast Cancer Symposium
Metastatic Voices: Research Advances and Public Policy
In 2016, Susan G. Komen® announced our bold goal: by 2026, reduce current rates of breast cancer mortality in the U.S. by 50%. Join us on October 5, 2018, for our first annual Breast Cancer Symposium in New Haven, CT. Attendees will learn about research advances, improving care experience for metastatic breast cancer patients, and advocacy work.
- Emerging strategies for early detection of breast cancer recurrence
- Crowd-sourcing metastatic breast cancer research
- Improving the care experience for metastatic breast cancer patients
- Effecting change through advocacy
Shirley Mertz, MA, JD
Shirley Mertz, a retired high school educator and principal, was treated for early stage breast cancer in 1991. Twelve years later, she received a metastatic breast cancer diagnosis. In 2004 she decided to use her voice and story to help others living with a metastatic diagnosis. In 2009 Shirley personally asked then Senator Evan Bayh to sponsor a resolution designating October 13th as National MBC Awareness Day. She successfully led a group of patients to Washington D.C. to lobby Congress to pass that national resolution.
Currently, Shirley works to empower patients and improve patient outcomes in several capacities. She is President of the Metastatic Breast Cancer Network; a member of the Executive Committee of the Metastatic Breast Cancer Alliance; Co-Chair of the MBC Alliance’s Research Task Force; a consumer reviewer for the DOD Breast Cancer Research Program and Komen Scientific Grants; a patient advocate representing the University of Chicago at the Translational Breast Cancer Research Consortium; and co-chair of the Scientific Committee for the Fifth International ABC5 Conference. In 2011 the White House honored Shirley as a Champion of Change in Breast Cancer. In 2016 Shirley received the John Mack Carter Founder’s Award from Komen Greater NYC.
Elizabeth Morris, MD, FACR
Elizabeth Morris is Chief, Breast Imaging Service and Larry Norton Chair at Memorial Sloan Kettering Cancer Center. She has pioneered high risk screening with MRI and offers screening with MRI, ultrasound, contrast enhanced digital mammography, and tomosynthesis. She has published studies on the use of MRI for staging breast cancer and for screening w omen at high risk for cancer.
Dr. Morris is a professor of radiology at Weill Cornell Medical College, and was elected a Fellow of the Society of Breast Imaging and of the American College of Radiology (ACR). She serves as Chair of the ACR MRI BI-RADS Lexicon committee and Vice President of the Society of Breast Imaging. These groups work to ensure that women throughout the country receive high-quality breast-imaging care. She lectures and teaches breast imaging radiologists widely, both nationally and internationally, on breast imaging and biopsy techniques.
Nikhil Wagle, MD
Nikhil Wagle is an Assistant Professor of Medicine at Harvard Medical School, a medical oncologist at Dana-Farber Cancer Institute, and an associate member of the Broad Institute of MIT and Harvard. He is the Deputy Director of the Center for Cancer Precision Medicine at Dana-Farber Cancer Institute.
Dr. Wagle leads The Metastatic Breast Cancer Project (mbcproject.org), a nationwide direct-to-patient research initiative that engages patients with advanced breast cancer through social media and seeks to empower them to accelerate cancer research through sharing their samples and clinical information. The project’s outreach program, developed in collaboration with advocacy organizations and patients, serves to connect thousands of patients around the U.S. with metastatic breast cancer research, allowing them to participate regardless of where they live.
Molly Williams is the Director of Advocacy and Professional Relations for Pfizer Inc. As part of Pfizer’s U.S. Government Relations team, Molly oversees advocacy outreach and development in a sixteen state region that spans from Maine to Kansas. Molly joined Pfizer from Wyeth where she was the Director of State Government Affairs for New York and Vermont. She began her career in the New York State Legislature in 1995 where she held several positions in both the Senate and Assembly. In addition, Molly worked as the Director of Public Policy at New York State Health Care Providers, Inc., and Assistant Director for Fiscal Policy and Communications at the Medical Society of the State of New York. Molly holds a B.A. and M.P.S. from Alfred University. She and her family live in Manchester, VT. Thomson Reuters report. He is a member of the Scientific Advisory Board of the Breast Cancer Research Foundation and a Susan Komen Scholar.
My name is Karen Peterson, and I was diagnosed with Triple Negative Breast Cancer in January 2015. Routine mammograms were a part of my health care routine due to my family’s history of cancer, which included the death of my maternal grandmother from metastatic breast and ovarian cancer in 1973 at the age 45. Prior to my breast cancer diagnosis I had lived a dual existence. On one hand, I was happy and blessed, engrossed in family, social events and a fulfilling job as a social worker serving my home community of Harlem, NY. On the other hand, I was a divorced single mom (once married to a hall-of-fame bound prime time radio disc jockey) who was trying to raise a son diagnosed with Autism. I had a keen understanding of heartache. Struggle had a continuous rotating invitation at my dinner table, and often hung around for dessert. Overcoming obstacles was an integral part of my DNA, which in turn would prepare me for the toughest fight of my life, staying alive after a TNBC diagnosis.” [Read More]